ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near London, England, GBR:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

London, United Kingdom and 51 other locations

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Sutton, Surrey, United Kingdom and 173 other locations

this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias...

Enrolling
Accelerated Phase Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Drug: Ponatinib

Phase 1, Phase 2

Incyte
Incyte

Sutton, United Kingdom and 32 other locations

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...

Active, not recruiting
Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

London, United Kingdom and 11 other locations

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Harrow, United Kingdom and 108 other locations

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...

Active, not recruiting
Acute Myeloid Leukemia
Drug: IMGN632
Drug: Venetoclax

Phase 1, Phase 2

AbbVie
AbbVie

Headington, United Kingdom and 30 other locations

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...

Active, not recruiting
Acute Myeloid Leukemia
Drug: S65487 and azacitidine

Phase 1, Phase 2

Servier
Servier

London, United Kingdom and 10 other locations

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

London, England, United Kingdom and 85 other locations

of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

London, United Kingdom and 119 other locations

with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Harrow, United Kingdom and 125 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems